NO20060023L - Fast preparat - Google Patents

Fast preparat

Info

Publication number
NO20060023L
NO20060023L NO20060023A NO20060023A NO20060023L NO 20060023 L NO20060023 L NO 20060023L NO 20060023 A NO20060023 A NO 20060023A NO 20060023 A NO20060023 A NO 20060023A NO 20060023 L NO20060023 L NO 20060023L
Authority
NO
Norway
Prior art keywords
solid preparation
hmg
particles containing
coa reductase
reductase inhibitor
Prior art date
Application number
NO20060023A
Other languages
English (en)
Norwegian (no)
Inventor
Hiroyoshi Koyama
Naoru Hamaguchi
Masafumi Misaki
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of NO20060023L publication Critical patent/NO20060023L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO20060023A 2003-06-06 2006-01-03 Fast preparat NO20060023L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2003162241 2003-06-06
PCT/JP2004/008076 WO2004108161A1 (ja) 2003-06-06 2004-06-03 固形製剤

Publications (1)

Publication Number Publication Date
NO20060023L true NO20060023L (no) 2006-03-06

Family

ID=33508660

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20060023A NO20060023L (no) 2003-06-06 2006-01-03 Fast preparat

Country Status (15)

Country Link
US (1) US20060280794A1 (pt)
EP (1) EP1642593A1 (pt)
KR (1) KR20060016787A (pt)
CN (1) CN1802178A (pt)
AU (1) AU2004244889A1 (pt)
BR (1) BRPI0410555A (pt)
CA (1) CA2528164A1 (pt)
IL (1) IL172206A0 (pt)
MA (1) MA27851A1 (pt)
MX (1) MXPA05013147A (pt)
NO (1) NO20060023L (pt)
RU (1) RU2005137865A (pt)
TW (1) TW200510002A (pt)
WO (1) WO2004108161A1 (pt)
ZA (1) ZA200508932B (pt)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7713547B2 (en) 2004-05-21 2010-05-11 Accu-Break Pharmaceuticals, Inc. Method of administering a partial dose of a segmented pharmaceutical tablet
US7780985B2 (en) * 2005-07-12 2010-08-24 Accu-Break Technologies, Inc. Tablets having a printed separation mark to guide breaking
AU2005245025B2 (en) * 2004-05-21 2010-06-03 Accu-Break Technologies, Inc. Pharmaceutical tablets comprising two or more unitary segments
US7622137B2 (en) * 2004-05-21 2009-11-24 Accu-Break Technologies, Inc. Dosage forms contained within a capsule or sachet
US7838031B2 (en) 2004-05-21 2010-11-23 Lawrence Solomon Method of administering a partial dose using a segmented pharmaceutical tablet
US7318935B2 (en) * 2004-05-21 2008-01-15 Accu-Break Technologies, Inc. Pharmaceutical tablets with active and inactive segments
US7329418B2 (en) * 2004-05-21 2008-02-12 Accu Break Technologies, Inc. Pharmaceutical tablets having height greater than width
KR100714616B1 (ko) * 2005-06-23 2007-05-07 삼성전기주식회사 지수 함수 발생기 및 이를 이용한 가변 이득 증폭기
CN1331476C (zh) * 2005-07-05 2007-08-15 凌沛学 一种辅酶a舌下含片及其制备方法
EP1948138A4 (en) * 2005-11-18 2012-07-11 Accu Break Technologies Inc SEGMENTED PHARMACEUTICAL DOSAGE FORMS
AR058605A1 (es) * 2005-12-22 2008-02-13 Takeda Pharmaceutical Preparacion solida
US20070237815A1 (en) * 2006-04-06 2007-10-11 Lawrence Solomon Dosage forms and methods comprising amlodipine and chlorthalidone
WO2008021875A2 (en) * 2006-08-08 2008-02-21 Accu-Break Technologies, Inc. Pharmaceutical tablets containing a plurality of active segments
CA2671092A1 (en) * 2006-11-30 2008-06-05 Accu-Break Technologies, Inc. Divisible osmotic dosage forms and methods of use
CA2672157C (en) * 2006-12-07 2016-07-26 Daiichi Sankyo Company, Limited Method for producing solid preparation
EA200970708A1 (ru) * 2007-01-24 2010-02-26 Др. Редди`С Лабораторис Лтд. Фармацевтические композиции, включающие аторвастатин и никотиновую кислоту
CL2008000684A1 (es) * 2007-03-09 2008-08-01 Indigene Pharmaceuticals Inc Composicion farmaceutica que comprende metformina r-(+) lipoato y un inhibidor de reductasa hmg-coa; formulacion de dosis unitaria; y uso en el tratamiento de una complicacion diabetica.
CN101632672B (zh) * 2008-07-24 2011-01-12 鲁南制药集团股份有限公司 一种用于治疗高血压的复方药物组合物
CA2782776A1 (en) 2008-12-04 2010-06-10 Ikfe Gmbh Biomarkers for atherosclerosis
AU2009325962A1 (en) 2008-12-11 2011-07-28 Ikfe Institut Fur Klinische Forschung Und Entwicklung Gmbh Biomarkers for insulin sensitizer drug response
EP2382467A1 (en) 2008-12-30 2011-11-02 IKFE GmbH Biomarkers for adipose tissue activity
US20100210541A1 (en) 2009-01-07 2010-08-19 Andreas Pfuetzner Biomarkers for Appetite Regulation
TR201005325A2 (tr) * 2010-06-30 2012-01-23 Bi̇lgi̇ç Mahmut Atorvastatin ve aspirin içeren farmasötik formülasyonlar
CN102028671A (zh) * 2010-12-27 2011-04-27 山东淄博新达制药有限公司 盐酸吡格列酮胶囊及其制备方法
ES2555927T3 (es) * 2011-01-20 2016-01-11 Bionevia Pharmaceuticals Inc. Composiciones de liberación modificada de epalrestat o un derivado del mismo y métodos para el uso de las mismas
US9339543B2 (en) 2011-10-12 2016-05-17 Merck Sharp & Dohme Corp. Pharmaceutical compositions that inhibit disproportionation
WO2013058409A1 (en) 2011-10-21 2013-04-25 Takeda Pharmaceutical Company Limited Sustained-release preparation
US20160331689A1 (en) * 2015-05-12 2016-11-17 SE Tylose USA, Inc. Aqueous enteric coating composition
US11160759B1 (en) 2015-10-09 2021-11-02 Combocap, Inc. Capsule with internal diaphragm for improved bioavailability
CN108421045B (zh) * 2018-04-02 2021-09-24 北京海晶生物医药科技有限公司 一种阿托伐他汀钙组合物、制剂及其制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4339428A (en) * 1980-08-18 1982-07-13 Bristol-Myers Company Capsule product containing high dosage of aspirin in powder or granulated form and alkaline tablet or pellet comprising magnesium carbonate, calcium carbonate and a magnesium dry component
US4294819A (en) * 1980-08-18 1981-10-13 Bristol-Myers Company Alkaline analgesic capsule
JPH05229936A (ja) * 1992-02-19 1993-09-07 Lion Corp 内服用顆粒製剤
WO1995011042A1 (en) * 1993-10-21 1995-04-27 Hisamitsu Pharmaceutical Co., Inc. Pernasal composition and pernasal preparation containing the same
US5593696A (en) * 1994-11-21 1997-01-14 Mcneil-Ppc, Inc. Stabilized composition of famotidine and sucralfate for treatment of gastrointestinal disorders
JP3651816B2 (ja) * 1995-07-03 2005-05-25 三共株式会社 動脈硬化症予防および治療剤
SE9804314D0 (sv) * 1998-12-14 1998-12-14 Astra Ab New pharmaceutical formulation
JP2001294537A (ja) * 2000-02-10 2001-10-23 Takeda Chem Ind Ltd 併用医薬
US8911781B2 (en) * 2002-06-17 2014-12-16 Inventia Healthcare Private Limited Process of manufacture of novel drug delivery system: multilayer tablet composition of thiazolidinedione and biguanides

Also Published As

Publication number Publication date
KR20060016787A (ko) 2006-02-22
TW200510002A (en) 2005-03-16
CA2528164A1 (en) 2004-12-16
AU2004244889A1 (en) 2004-12-16
IL172206A0 (en) 2006-04-10
MXPA05013147A (es) 2006-03-17
WO2004108161A1 (ja) 2004-12-16
US20060280794A1 (en) 2006-12-14
ZA200508932B (en) 2007-03-28
EP1642593A1 (en) 2006-04-05
CN1802178A (zh) 2006-07-12
MA27851A1 (fr) 2006-04-03
BRPI0410555A (pt) 2006-06-20
RU2005137865A (ru) 2006-06-10

Similar Documents

Publication Publication Date Title
NO20060023L (no) Fast preparat
CY1108361T1 (el) ΣΤΑΘΕΡΟ ΣΚΕΥΑΣΜΑ ΠΟΥ ΠΕΡΙΕΧΕΙ TNFR-Fc ΚΑΙ ΑΡΓΙΝΙΝΗ
WO2006137934A3 (en) Purposeful movement of human migratory cells away from an agent source
TW200745161A (en) Stable antibody formulation
EA200701790A1 (ru) Твёрдый фармацевтический дозированный состав
WO2007133290A3 (en) Anti-ox40l antibodies and methods using same
WO2006083936A3 (en) Anti-ephb2 antibodies and methods using same
ITPD20020138A0 (it) Composizione di sostanze a base terpenica, metodo di preparazione e metodo di dispersione in ambiente della medesima.
IL214325A (en) Antibody against cmet, a drug that includes and uses it
WO2005066151A3 (en) Histone deacetylase inhibitors
WO2006042206A3 (en) Systems and methods for direct restoration of foraminal volume
HRP20080564T3 (hr) Dihidrotetrabenazini i farmaceutski pripravci koji ih sadrže
SV2004001473A (es) Composiciones farmaceuticas de inhibidores de la proteina de transferencia de esteres de colesterilo ref.pc 23132
BRPI0413468A (pt) inibidores de hmg-coa redutase baseados em pirrol
MXPA05011212A (es) Derivados de indeno como agentes farmaceuticos.
NO20075140L (no) Fremgangsmater og preparater for modulering av vaskulaer integritet
WO2004047772A3 (en) Catalytic antioxidants and methods of use
AU2007310767A1 (en) New fluorene derivatives, compositions containing the same and use thereof as inhibitors of the protein chaperone HSP 90
WO2003047517A3 (en) Novel-n-[4-(1h-imidazol-1-yl)-2-fluorophenyl]-3-(trifluoromethyl)-1-h-pyrazole-5-carboxamides as factor xa
EP1254667A4 (en) MEDICINE COMPRISING A COMBINATION
WO2007053570A3 (en) A polypeptide complex of trpm8 and calmodulin and its uses thereof
WO2003017925A3 (en) Treatment of type i diabetes
ATE499341T1 (de) 5-(2,2-dimethyl-cyclopropyl)-3-methylpent-2- ennitril als geruchs- und geschmacksstoff
EA200501088A1 (ru) Цетилпиридиниевая соль противоспалительного средства и фармацевтические композиции, содержащие ее
AU2003261894A1 (en) Optical isolator, and laser oscillator using this

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application